Spironolactone, but not eplerenone, impairs glucose tolerance in a rat model of metabolic syndrome

Journal of Veterinary Medical Science

Volumn 74, Issue 8, 2012, Pages 1015-1022

  Homma, Tsuyoshi ^a,b   Fujisawa, Michio ^b   Arai, Kiyoshi ^b   Ishii, Marie ^b   Sada, Toshio ^b   Ikeda, Masahiro ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Blood glucose; Eplerenone; Metabolic syndrome; Mineralocorticoid receptor; Spironolactone

Indexed keywords

DRUG DERIVATIVE; EPLERENONE; GLUCOSE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SODIUM; SPIRONOLACTONE;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; CHEMICALLY INDUCED DISORDER; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; METABOLIC SYNDROME X; METABOLISM; RAT; URINE;

ANIMALS; AREA UNDER CURVE; BLOOD GLUCOSE; GLUCOSE; GLUCOSE INTOLERANCE; METABOLIC SYNDROME X; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; RATS; SODIUM; SPIRONOLACTONE;

EID: 84867885350     PISSN: 09167250     EISSN: 13477439     Source Type: Journal    
DOI: 10.1292/jvms.12-0007     Document Type: Article

References (33)

1. Auchus, R. J. and Nwariaku, F. E. 2007. Primary aldosteronism. Curr. Cardiol. Rep. 9: 447-452. [Medline] [CrossRef]
2. Bertocchio, J. P., Warnock, D. G. and Jaisser, F. 2011. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int. 79: 1051-1060. [Medline] [CrossRef]
3. Bhathena, S. J., Kennedy, B. W., Jones, J., Smith, P. M., Michaelis, O. E. 4th, Carswell, N., Hansen, C. T., Voyles, N. R. and Recant, L. 1989. Effect of dietary carbohydrates on insulin and glucagon receptors in a new model of noninsulin-dependent diabetes-SHR/N-corpulent rat. Proc. Soc. Exp. Biol. Med. 192: 66-71. [Medline]
4. Briet, M. and Schiffrin, E. L. 2011. The role of aldosterone in the metabolic syndrome. Curr. Hypertens. Rep. 13: 163-172. [Medline] [CrossRef]
5. Caprio, M., Antelmi, A., Chetrite, G., Muscat, A., Mammi, C., Marzolla, V., Fabbri, A., Zennaro, M. C. and Feve, B. 2011. Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome. Endocrinology 152: 113-125. [Medline] [CrossRef]
6. Chapman, N., Dobson, J., Wilson, S., Dahlof, B., Sever, P. S., Wedel, H. and Poulter, N. R. 2007. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49: 839-845. [Medline] [CrossRef]
7. Corry, D. B. and Tuck, M. L. 2003. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 5: 106-109. [Medline] [CrossRef]
8. Davies, J. I., Band, M., Morris, A. and Struthers, A. D. 2004. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47: 1687-1694. [Medline] [CrossRef]
9. Delyani, J. A., Rocha, R., Cook, C. S., Tobert, D. S., Levin, S., Roniker, B., Workman, D. L., Sing, Y. L. and Whelihan, B. 2001. Eplerenone: a selective aldosterone receptor antagonist (SARA). Cardiovasc. Drug Rev. 19: 185-200. [Medline] [CrossRef]
10. Dietz, J. D., Du, S., Bolten, C. W., Payne, M. A., Xia, C., Blinn, J. R., Funder, J. W. and Hu, X. 2008. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 51: 742-748. [Medline] [CrossRef]
11. Fallo, F., Veglio, F., Bertello, C., Sonino, N., Della Mea, P., Ermani, M., Rabbia, F., Federspil, G. and Mulatero, P. 2006. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91: 454-459. [Medline] [CrossRef]
12. Fuller, P. J., Lim-Tio, S. S. and Brennan, F. E. 2000. Specificity in mineralocorticoid versus glucocorticoid action. Kidney Int. 57: 1256-1264. [Medline] [CrossRef]
13. Guo, C., Ricchiuti, V., Lian, B. Q., Yao, T. M., Coutinho, P., Romero, J. R., Li, J., Williams, G. H. and Adler, G. K. 2008. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferatoractivated receptor-gamma, and proinflammatory adipokines. Circulation 117: 2253-2261. [Medline] [CrossRef]
14. Hirata, A., Maeda, N., Hiuge, A., Hibuse, T., Fujita, K., Okada, T., Kihara, S., Funahashi, T. and Shimomura, I. 2009. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc. Res. 84: 164-172. [Medline] [CrossRef]
15. Karim, A. 1978. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab. Rev. 8: 151-188. [Medline] [CrossRef]
16. Levine, D., Ramsay, L., Auty, R., Branch, R. and Tidd, M. 1976. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone. Eur. J. Clin. Pharmacol. 09: 381-386. [Medline] [CrossRef]
17. Livingstone, C. and Collison, M. 2002. Sex steroids and insulin resistance. Clin. Sci. 102: 151-166. [Medline] [CrossRef]
18. Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L. and Toto, R. D. 2009. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 20: 2641-2650. [Medline] [CrossRef]
19. Meyers, M. J., Arhancet, G. B., Hockerman, S. L., Chen, X., Long, S. A., Mahoney, M. W., Rico, J. R., Garland, D. J., Blinn, J. R., Collins, J. T., Yang, S., Huang, H. C., McGee, K. F., Wendling, J. M., Dietz, J. D., Payne, M. A., Homer, B. L., Heron, M. I., Reitz, D. B. and Hu, X. 2010. Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-b enzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy. J. Med. Chem. 53: 5979-6002. [Medline] [CrossRef]
20. Michaelis, O. E. 4th, Ellwood, K. C., Judge, J. M., Schoene, N. W. and Hansen, C. T. 1984. Effect of dietary sucrose on the SHR/N-corpulent rat: a new model for insulin-independent diabetes. Am. J. Clin. Nutr. 39: 612-618. [Medline]
21. Nagase, M., Yoshida, S., Shibata, S., Nagase, T., Gotoda, T., Ando, K. and Fujita, T. 2006. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17: 3438-3446. [Medline] [CrossRef]
22. Nariai, T., Fujita, K., Mori, M., Katayama, S., Hori, S. and Matsui, K. 2011. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity. J. Pharmacol. Sci. 115: 346-353. [Medline] [CrossRef]
23. Pajvani, U. B. and Scherer, P. E. 2003. Adiponectin: systemic contributor to insulin sensitivity. Curr. Diab. Rep. 3: 207-213. [Medline] [CrossRef]
24. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J. and Gatlin, M. 2003. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348: 1309-1321. [Medline] [CrossRef]
25. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. 1999. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341: 709-717. [Medline] [CrossRef]
26. Preiss, D., Zetterstrand, S., McMurray, J. J., Ostergren, J., Michelson, E. L., Granger, C. B., Yusuf, S., Swedberg, K., Pfeffer, M. A., Gerstein, H. C. and Sattar, N. 2009. Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care 32: 915-920. [Medline] [CrossRef]
27. Ramsay, L. E., Hessian, P. and Tidd, M. J. 1975. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses. Br. J. Clin. Pharmacol. 2: 271-276. [Medline]
28. Struthers, A., Krum, H. and Williams, G. H. 2008. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 31: 153-158. [Medline] [CrossRef]
29. Takaya, K., Ogawa, Y., Hiraoka, J., Hosoda, K., Yamori, Y., Nakao, K. and Koletsky, R. J. 1996. Nonsense mutation of leptin receptor in the obese spontaneously hypertensive Koletsky rat. Nat. Genet. 14: 130-131. [Medline] [CrossRef]
30. Wada, T., Hori, S., Sugiyama, M., Fujisawa, E., Nakano, T., Tsuneki, H., Nagira, K., Saito, S. and Sasaoka, T. 2010. Progesterone inhibits glucose uptake by affecting diverse steps of insulin signaling in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 298: E881-E888. [Medline] [CrossRef]
31. Wada, T., Kenmochi, H., Miyashita, Y., Sasaki, M., Ojima, M., Sasahara, M., Koya, D., Tsuneki, H. and Sasaoka, T. 2010. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology 151: 2040-2049. [Medline] [CrossRef]
32. Yamaji, M., Tsutamoto, T., Kawahara, C., Nishiyama, K., Yamamoto, T., Fujii, M. and Horie, M. 2010. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A(c) levels in patients with chronic heart failure. Am. Heart J. 160: 915-921. [Medline] [CrossRef]
33. Zannad, F., McMurray, J. J., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J. and Pitt, B. 2011. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364: 11-21. [Medline] [CrossRef]